Stem Cell Clinic

Rocket Pharmaceuticals Announces First Patient Treated in Global Registrational Phase 2 Study of RP-L102 Process B for Fanconi Anemia – BioSpace

By Somatic Stem Cells

NEW YORK--(BUSINESS WIRE)-- Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (Rocket), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces that the first patient in the global Phase 2 registration-enabling study of RP-L102 Process B received investigational therapy. RP-L102 is the Companys lentiviral vector (LVV)-based gene therapy for the treatment of Fanconi Anemia (FA).

The initiation of Rockets first Phase 2 trial is an important milestone for the company as well as patients throughout the world battling FA, said Kinnari Patel, Pharm.D., MBA, Chief Operating Officer and Head of Development of Rocket. With the recent feedback received from the FDA and EMA of MMC-resistance as the primary endpoint, we are optimistic about the prospect of benefiting patients and, if the data are positive, working towards BLA and MAA submissions.

The registrational package will include twelve patients from the U.S. and EU, two from the U.S. Phase 1 study and 10 additional patients from the global Phase 2 study (NCT04069533). Patients will receive a single intravenous infusion of RP-L102 that utilizes fresh cells and Process B which incorporates a modified stem cell enrichment process, transduction enhancers, as well as commercial-grade vector and final drug product. Improved mitomycin-C (MMC) resistance in bone marrow colony forming (progenitor) cells is the primary endpoint, and may also serve as a surrogate endpoint for accelerated approval. Additional outcome measures include stability or increase in blood counts with no significant worsening in anemia, neutropenia or thrombocytopenia and peripheral blood and bone marrow genetic correction, as demonstrated by progressive increases in vector copy number (VCN) over the months subsequent to infusion.

Lucile Packard Childrens Hospital Stanford and Hospital Infantil Universitario Nio Jess are serving as the lead clinical sites and University of Minnesota is conducting centralized evaluation of bone marrow MMC-resistance and engaging in advisory activities for the global trial of RP-L102. RP-L102 was in-licensed from the Centro de Investigaciones Energticas, Medioambientales y Tecnolgicas (CIEMAT), Centro de Investigacin Biomdica en Red de Enfermedades Raras (CIBERER), Instituto de Investigacin Sanitaria Fundacin Jimnez Daz (IIS-FJD) and Fundacion para la Investigacion Biomedica Hospital Infantil Universitario Nio Jesus (FIB-HIUNJ).

About Fanconi Anemia

Fanconi Anemia (FA) is a rare pediatric disease characterized by bone marrow failure, malformations and cancer predisposition. The primary cause of death among patients with FA is bone marrow failure, which typically occurs during the first decade of life. Allogeneic hematopoietic stem cell transplantation (HSCT), when available, corrects the hematologic component of FA, but requires myeloablative conditioning, which is highly toxic for the patient. HSCT is frequently complicated by graft versus host disease and also increases the risk of solid tumors, particularly upper aerodigestive tract squamous cell carcinomas. Approximately 60-70% of patients with FA have a FANCA gene mutation, which encodes for a protein essential for DNA repair. Mutations in the FANCA gene leads to chromosomal breakage and increased sensitivity to oxidative and environmental stress. Chromosome fragility induced by DNA-alkylating agents such as mitomycin-C (MMC) or diepoxybutane (DEB) is the gold standard test for FA diagnosis. These assays can further differentiate FA patients from mosaic patients. Somatic mosaicism occurs when there is a spontaneous reversion mutation that can lead to a mixed chimerism of corrected and uncorrected bone marrow cells leading to stabilization or correction of an FA patients blood counts in the absence of any administered therapy. Somatic mosaicism provides strong rationale for the development of FA gene therapy and demonstrates the selective advantage of gene-corrected hematopoietic cells in FA1.

1Soulier, J.,et al. (2005) Detection of somatic mosaicism and classification of Fanconi anemia patients by analysis of the FA/BRCA pathway. Blood 105: 1329-1336

About Rocket Pharmaceuticals, Inc.

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (Rocket) is advancing an integrated and sustainable pipeline of genetic therapies that correct the root cause of complex and rare childhood disorders. The companys platform-agnostic approach enables it to design the best therapy for each indication, creating potentially transformative options for patients contending with rare genetic diseases. Rocket's clinical programs using lentiviral vector (LVV)-based gene therapy are for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer, Leukocyte Adhesion Deficiency-I (LAD-I), a severe pediatric genetic disorder that causes recurrent and life-threatening infections which are frequently fatal, and Pyruvate Kinase Deficiency (PKD) a rare, monogenic red blood cell disorder resulting in increased red cell destruction and mild to life-threatening anemia. Rockets first clinical program using adeno-associated virus (AAV)-based gene therapy is for Danon disease, a devastating, pediatric heart failure condition. Rockets pre-clinical pipeline program is for Infantile Malignant Osteopetrosis (IMO), a bone marrow-derived disorder. For more information about Rocket, please visit http://www.rocketpharma.com.

Rocket Cautionary Statement Regarding Forward-Looking Statements

Various statements in this release concerning Rocket's future expectations, plans and prospects, including without limitation, Rocket's expectations regarding the safety, effectiveness and timing of product candidates that Rocket may develop, to treat Fanconi Anemia (FA), Leukocyte Adhesion Deficiency-I (LAD-I), Pyruvate Kinase Deficiency (PKD), Infantile Malignant Osteopetrosis (IMO) and Danon disease, and the safety, effectiveness and timing of related pre-clinical studies and clinical trials, may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws and are subject to substantial risks, uncertainties and assumptions. You should not place reliance on these forward-looking statements, which often include words such as "believe," "expect," "anticipate," "intend," "plan," "will give," "estimate," "seek," "will," "may," "suggest" or similar terms, variations of such terms or the negative of those terms. Although Rocket believes that the expectations reflected in the forward-looking statements are reasonable, Rocket cannot guarantee such outcomes. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, Rocket's ability to successfully demonstrate the efficacy and safety of such products and pre-clinical studies and clinical trials, its gene therapy programs, the pre-clinical and clinical results for its product candidates, which may not support further development and marketing approval, the potential advantages of Rocket's product candidates, actions of regulatory agencies, which may affect the initiation, timing and progress of pre-clinical studies and clinical trials of its product candidates, Rocket's and its licensors ability to obtain, maintain and protect its and their respective intellectual property, the timing, cost or other aspects of a potential commercial launch of Rocket's product candidates, Rocket's ability to manage operating expenses, Rocket's ability to obtain additional funding to support its business activities and establish and maintain strategic business alliances and new business initiatives, Rocket's dependence on third parties for development, manufacture, marketing, sales and distribution of product candidates, the outcome of litigation, and unexpected expenditures, as well as those risks more fully discussed in the section entitled "Risk Factors" in Rocket's Quarterly Report on Form 10-Q for the quarter ended September 30, 2019, filed November 8, 2019. Accordingly, you should not place undue reliance on these forward-looking statements. All such statements speak only as of the date made, and Rocket undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20191206005080/en/

Here is the original post:
Rocket Pharmaceuticals Announces First Patient Treated in Global Registrational Phase 2 Study of RP-L102 Process B for Fanconi Anemia - BioSpace

Brave new world? Why the public might be ready for gene-edited babies – Genetic Literacy Project

By Somatic Stem Cells

Should we be able to genetically design our children before they are born giving them the eye and hair color we prefer, deciding their sex and height, and even genetically manipulating their intelligence? Most, including top scientists and genetic counselors, say no. But what if the genetic manipulation was done in order to cure a debilitating or potentially fatal illness before the individual was even born? And what if this one genetic treatment could save the individuals descendants from inheriting the disorder, too? A 2018 meeting of non-scientists in Germany indicated that public opinion may be moving in the yes direction.

Though gene editing technology isnt yet at the point where we can genetically alter unborn individuals at the clinical level by applying gene editing tools like CRISPR/Cas9 to embryos, sperm or egg cells the technology is rapidly advancing.

Debate over the subject was rekindled last year, when a Chinese researcher announced that he used CRISPR to create the worlds first gene-edited babies. According to the Associated Press, He Jiankui said he altered embryos for seven couples during fertility treatments. The treatment was designed to protect the children of an HIV-positive parent by disabling a gene that would have allowed the virus to enter their cells. The trial resulted in one pregnancy twins who were born in November. According to the Associated Press, the researcher said:

I feel a strong responsibility that its not just to make a first, but also make it an example. Society will decide what to do next.

The gene-editing community has grappled with the unexpected announcement in the following months. It was not well received by other researchers, with many of them condemning the action. Feng Zhang, one of the inventors of CRISPR, called for an moratorium on gene-edited babies. Zhang wrote:

Not only do I see this as risky, but I am also deeply concerned about the lack of transparency surrounding this trial. All medical advances, gene editing or otherwise and particularly those that impact vulnerable populations, should be cautiously and thoughtfully tested, discussed openly with patients, physicians, scientists, and other community members, and implemented in an equitable way.

Its not unusual to see articles and reports in the media focusing on the worst possible scenarios when it comes to genome editing, as is often the case with new or particularly disruptive technologies. The mere mention of the topic tends to incite fears of a New Eugenics master race or exacerbation of medical inequalities along class lines where the poor are barred from genetic interventions and the rich have easy access. Still others, such as some Catholic and Muslim groups, worry that genetic manipulation of any sort is interfering with divine plans.

These kinds of fears have been gradually loosening their hold on our imaginations, while the coolly-measured possibilities of gene editing nothing more than a new and innovative medical tool are winning over. And as with any new technology, it comes with a particular set of risks and benefits that must be taken into consideration. The slow change in public attitude toward gene editing is evident in groups such as Germanys Citizens Delphi Germline Therapy project at Karlsruhe Institute of Technology (KIT).

After debating detailed information on the risks and benefits over the course of a few months, and undergoing a rigorous participation process that combined aspects of Citizens Jury with the Delphi survey method, the group has called for the loosening of bans on germline gene editing research in Germany. Their final report was presented at Berlin Science Week in late 2018. And though their verdict only applies to the current ban in Germany, which includes a ban on basic research in germline cells, the groups decision could have an impact on regulations around the world. Indeed, the participants were keen on having Germany play a more active role in the development of international gene editing guidelines.

Regarding the Citizens Jury and Delphi survey methods used, Ralf Grtker, who developed and carried out the project in collaboration with the Department of Science Communication at the Institute for German Studies at KIT, stated, The process is geared towards working on a complex topic with a group of laypeople, empower them to make an informed judgment, and eventually reach recommendations for politicians. Though the group only consisted of 26 German citizens, the group was representative of the population, and the topic of gene editing was thoroughly investigated from a variety of angles.

The group acknowledged the risks of genome editing, such as unknown and off-target effects, but ultimately agreed that the way forward was to open the doors to germline gene editing research at the national and global levels. Their conclusions also echoed those made by genetics experts in a position statement published in the August 2017 issue of the American Journal of Human Genetics, which stated, At this time, given the nature and number of unanswered scientific, ethical, and policy questions, it is inappropriate to perform germline gene editing that culminates in human pregnancy.

But to answer those scientific, ethical, and policy questions, basic research is crucial. And lines of communication need to be open between countries, and between scientists and non-scientists. Without these measures, misunderstandings and missed clinical opportunities will proliferate, along with the dangers of underground gene editing and gene editing tourism. Several governments around the world are grappling with heated and unresolved debates regarding germline gene editing, which in several cases appear to be impeding research.

Though a great deal of cooperation and knowledge exchange is taking place between countries, other nations have yet to move away from all-out bans on germline gene editing. Canada, for example, has criminalized germline gene editing under the 2004 Assisted Human Reproduction Act. Penalties for the crime of germline gene tampering include a $500,000 CAD fine and up to 10 years of jail time.

Following a presentation at the annual Till & McCulloch Meetings of stem-cell and regenerative-medicine researchers, Bartha Knoppers, a health policy expert at McGill University in Montreal, said, Canadas policy has simply shut down discussion (about gene editing). We need to start to talk. Some Canadian scientists worry that Canada is lagging behind in gene editing research, unable to fully participate in the global conversation taking place on this important subject.

At the other end of the spectrum are countries like Japan, where a proposal allowing for the use of gene editing tools in human embryos has been drafted. The new guidelines would restrict manipulation of human embryos for reproduction, though this restriction would likely not be legally binding.

Though several countries have formal bans in place restricting germline gene editing, many of these same countries allow for somatic (or non-reproductive) gene editing applications, which is when gene editing tools are applied to adult cells. Somatic gene edits are not passed on to future generations, so there is less concern about the possible repercussions.

A version of this article previously ran on the GLP on Nov 27, 2018.

Kristen Hovet covers genetics, medical innovations, and the intersection of sociology and culture. Follow her on her website or Twitter @kristenhovet

Here is the original post:
Brave new world? Why the public might be ready for gene-edited babies - Genetic Literacy Project

Must-Reads Of The Week From Brianna Labuskes – Kaiser Health News

By Stem Cell Clinics

Happy Friday! Hope everyone had a lovely, restful Thanksgiving. And heres your periodic (and Im sure very appreciated and not at all tiresome) reminder not to be one of the nearly 40% of Americans who plan to skip their flu shot.

Now on to our jam-packed week of news! Heres what you might have missed.

There seems to be some conflicting narrative around what exactly a new health care spending analysis means, but one thing is clear: We are now spending $11,172 per person and that is uh a lot, to say the least. Spending on health care grew at a slower pace than the economy overall. But the spending didnt increase because people were going to the doctor more. Instead, price hikes made up for the slower usage growth found by the HHS analysis.

If you want a good plain-English breakdown of what this means, check out this Axios summary of it all; they do a better job than I could. (No one told me thered be math!) Or listen to KHNs What The Health podcast by our fabulously knowledgeable Julie Rovner.

The New York Times: Health Spending Grew Modestly, New Analysis Finds

Axios: Health care spending grew at a faster rate in 2018

KHN: What The Health?: We Spend HOW MUCH On Health Care?

Speaking of outrageous hospital prices, in a move that shocked no one, hospitals officially filed a suit against the Trump administration rule that would compel them to share secretly negotiated prices for procedures.

The New York Times: Hospitals Sue Trump to Keep Negotiated Prices Secret

There has been an absolute flood of news out of the Trump administration this week, so buckle up.

Nearly 700,000 Americans are slated to lose their food stamp benefits under a new rule that tightens the work requirements in the Supplemental Nutrition Assistance Program (commonly known as SNAP). The move will purportedly save the government $5.5 billion over five years. The Agriculture Department defended the decision to crack down on waivers that extend the time a beneficiary can receive aid as, essentially, if not now (when the economy is good), then when?

Critics were quick to point out the economic and moral pitfalls of this kind of decision, among them being: Most beneficiaries work, and many of the ones who dont usually have a reason beyond wanting the $1.83 per meal that they receive under SNAP; its been shown that SNAP spending helps cushion the economy during a recession; and the people being cut off are among the most vulnerable in our society.

The Associated Press: 668,000 will lose food stamp benefits under new work rules

As part of the administrations goal to eradicate the HIV epidemic, HHS announced that uninsured Americans can now get free HIV-prevention drugs. While PrEP has been shown to be wildly successful, many people who are at high risk of contracting the virus arent taking the drug for one reason or another.

(I wonder if this is all a bit awkward, considering that HHS and PrEPs maker are locked in a bitter patent battle.)

The New York Times: 200,000 Uninsured Americans to Get Free H.I.V.-Prevention Drugs

Attorney General William Barr made waves when he suggested that communities upset with police brutality might lose protections from the cops theyre protesting. The remarks which seemed to encourage abandonment as a form of retribution for those seeking criminal justice reform were quickly condemned as dangerous.

The New York Times: Barr Says Communities That Protest the Police Risk Losing Protection

A new investigation from Reuters found that the FDA ignored warning bells about the dangers of talc as early as the 1970s. The agency for decades deferred to the industry over outside experts advice.

Reuters: FDA bowed to industry for decades as alarms were sounded over talc

And a disturbing video obtained by ProPublica contradicts the Border Patrols account of the death of a sick 16-year-old who was being held in U.S. custody. The video shows the boy staggering to the toilet and collapsing on the floor, where he remained in the same position for the next four-and-a-half hours. According to ProPublica, The video shows the only way CBP officials could have missed Carlos crisis is that they werent looking. Border Patrol also said it was agents who found his body but in reality a cellmate alerted them to his death.

ProPublica: Inside the Cell Where a Sick 16-Year-Old Boy Died in Border Patrol Care

Meanwhile, new documents reveal how a powerhouse consulting firm proposed money-saving methods for the detention centers that included proposed cuts in spending on food for migrants, as well as on medical care and supervision of detainees.

ProPublica: How McKinsey Helped the Trump Administration Detain and Deport Immigrants

Over on the presidential campaign trail, Medicare for All continues to trip up the candidates, including Sen. Elizabeth Warren (D-Mass.), whose fate seems to have become tied to the proposal, which wasnt even hers to start with. Politico takes us all the way back to a town hall in 2017 hosted by Sen. Kamala Harris (D-Calif.) to figure out how we got to where we are today.

Politico: The most consequential moment of the 2020 primary

The Washington Post: How a fight over health care entangled Elizabeth Warren and reshaped the Democratic presidential race

Meanwhile, some Dems in the race are touting a public option as a moderate alternative to Medicare for All, but dont let that fool you. That kind of shift could still send an earthquake through the health care landscape.

The New York Times: Why the Less Disruptive Health Care Option Could Be Plenty Disruptive

Gains made by the anti-abortion movement in recent years are often attributed to a well-executed ground game by the right. But there have also been crucial missteps on the other side of the abortion wars. Critics say that the national abortion rights movement lost touch with the ways access was steadily eroding in Republican strongholds, and that leaders grew overconfident during Barack Obamas presidency. As one director of a clinic in Atlanta told The New York Times: We were screaming at the top of our lungs, everything is not fine, please pay attention.

The New York Times: How a Divided Left Is Losing the Battle on Abortion

Theres been a ton of buzz around the first major gun case the Supreme Court took up in nearly a decade. But will it all be for naught? Arguments in the case, which centers around a NYC handgun ordinance, focused on the fact that the city got rid of the contested limits in July.

Reuters: U.S. Supreme Court justices debate whether to dismiss major gun case

I have to say I did not expect to read the phrase we are feared as a tiger with claws, teeth and balls when I kicked off my workweek, but here we are. As seems to be the case every time we get unsealed documents dealing with the Sackler family, the newest ones reveal how deeply involved Richard Sackler was in the aggressive push to market OxyContin.

Stat: Purdues Richard Sackler proposed plan to play down OxyContin risks, and wanted drug maker feared like a tiger, files show

So often opioid news focuses on the big players and court cases these days. But in this article, people who were high school kids at the time the epidemic was really starting to brew talk about how their lives have been irrevocably changed by the crisis.

The New York Times: The Class of 2000 Could Have Been Anything. Until Opioids Hit.

Despite the fact that it seems warnings are everywhere about the dangers of vaping, a new survey reveals that nearly 1 in 3 teens have used a tobacco product recently. Whats more, many students said they did not consider intermittent smoking of any product to be harmful.

The New York Times: Nearly a Third of Teens Use One or More Tobacco Products

In the miscellaneous file for the week:

In Rhode Island, 11 patients over a two-and-a-half-year span died because of a misplaced breathing tube (something thats never supposed to happen in emergency medicine). The state is the only one in New England to allow responders other than the most highly trained paramedics to place the tubes. But advocates say that, if they tighten those rules, it will cost even more lives, because fewer patients will have access to the equipment.

ProPublica: EMS Crews Brought Patients to the Hospital With Misplaced Breathing Tubes. None of Them Survived.

Every once in a while were hit with a story that reminds us that relying on technology especially when it comes to health care is a dangerous game despite the benefits it brings. This time it was a glitch with diabetes monitors.

Stat: A glitch in diabetes monitors serves as a cautionary tale for health tech

Patients who are desperate for a miracle are being given tips by stem cell clinics on how to raise enough money to afford unproven, and sometimes dangerous, treatments. Theres always GoFundMe, the clinics say when met with the patients financial barriers.

The Washington Post: Clinic pitches unproven treatments to desperate patients, with tips on raising the cash

Thats it from me! Have a great weekend.

Read the original here:
Must-Reads Of The Week From Brianna Labuskes - Kaiser Health News

Brenner and Rector’s The Kidney, 2-Volume Set. Edition No. 11 – ResearchAndMarkets.com – Associated Press

By Adult Stem Cells

DUBLIN--(BUSINESS WIRE)--Dec 6, 2019--

The Brenner and Rectors The Kidney, 2-Volume Set. Edition No. 11 book has been added to ResearchAndMarkets.coms offering.

Put the worlds most well-known kidney reference to work in your practice with the 11th Edition of Brenner & Rectors The Kidney. This two-volume masterwork provides expert, well-illustrated information on everything from basic science and pathophysiology to clinical best practices. Addressing current issues such as new therapies for cardiorenal syndrome, the increased importance of supportive or palliative care in advanced chronic kidney disease, increasing live kidney donation in transplants, and emerging discoveries in stem cell and kidney regeneration, this revised edition prepares you for any clinical challenge you may encounter.

Key Topics Covered:

1. Embryology of the Kidney

2. Anatomy of the Kidney

3. The Renal Circulations and Glomerular Ultrafiltration

4. Glomerular Cell Biology

5. Metabolic Basis of Solute Transport

6. Transport of Sodium, Chloride, and Potassium

7. The Regulation of Calcium, Magnesium, and Phosphate Excretion by the Kidney

8. Renal Handling of Organic Solutes

9. Renal Acidification Mechanisms

10. Urine Concentration and Dilution and The Cell Biology of Vasopressin Action

11. Vasoactive Molecules and the Kidney

12. Aldosterone and Mineralocorticoid Receptors: Renal and Extrarenal Roles

13. Arachidonic Acid Metabolites and the Kidney

14. Disorders of Sodium Balance

15. Disorders of Water Balance

16. Disorders of Acid-Base Balance

17. Disorders of Potassium Balance

18. Disorders of Calcium, Magnesium, and Phosphate Balance

19. Epidemiology of Kidney Disease

20. Risk Prediction in Chronic Kidney Disease

21. Developmental Programming of Blood Pressure and Renal Function

22. Physiology and Pathophysiology of the Aging Kidney

23. Clinical Approach and Laboratory Assessment of the patient with kidney disease

24. Interpretation of Electrolyte and Acid-Base Parameters in Blood and Urine

25. Diagnostic Kidney Imaging

26. The Kidney Biopsy

27. Biomarkers in Acute and Chronic Kidney Diseases

28. Pathophysiology of Acute Kidney Injury

29. Prevention and Management of Acute Kidney Injury

30. Pathophysiology of Proteinuria

31. Primary Glomerular Disease

32. Secondary Glomerular Disease

33. Overview of Therapy for Glomerular Disease

34. Thrombotic Microangiopathy and Microvascular Disease

35. Tubulointerstitial Diseases

36. Urinary Tract Infection in Adults

37. Urinary Tract Obstruction

38. Urinary Stone Disease

39. Diabetic Nephropathy

40. Cardiorenal Syndromes

41. Kidney Cancer

42. Onco-Nephrology: Kidney Disease in Patients with Cancer

43. Inherited Disorders of the Glomerulus

44. Inherited Disorders of the Renal Tubule

45. Cystic Diseases of the Kidney

46. Primary and Secondary Hypertension

47. Renovascular Hypertension and Ischemic Nephropathy

48. Pregnancy and Kidney Disease

49. Antihypertensive Therapy

50. Diuretics

51. Mechanisms of Progression of Chronic Kidney Disease

52. The Pathophysiology of Uremia

53. Chronic Kidney Disease-Mineral Bone Disorder

54. Cardiovascular Aspects of Kidney Disease

55. Hematologic Aspects of Kidney Disease

56. Endocrine Aspects of Chronic Kidney Disease

57. Neurologic Aspects of Kidney Disease

58. Dermatologic Conditions in Kidney Disease

59. Staging and Management of Chronic Kidney Disease

60. Dietary Approaches to Kidney Diseases

61. Drug Dosing Considerations in Patients with Acute Kidney Injury and Chronic Kidney Disease

62. Supportive Care in Advanced Kidney Disease

63. Hemodialysis

64. Peritoneal Dialysis

65. Critical Care Nephrology

66. Plasmapheresis

67. Elimination Enhancement of Poisons

68. Interventional Nephrology

69. Transplantation Immunobiology

70. Clinical Management of the Adult Kidney Transplant Recipient

71. Considerations in Live Kidney Donation

72. Diseases of the Kidney and Urinary Tract in Children

73. Fluid, Electrolyte, and Acid-Base Disorders in Children

74. Renal Replacement Therapy (Dialysis and Transplantation) in Pediatric End-Stage Kidney Disease

75. Global Challenges and Initiatives in Kidney Health

76. Latin America

77. Africa

78. Near and Middle East

79. Indian Subcontinent

80. Far East

81. Oceania Region

82. Ethical Dilemmas Facing Nephrology: Past, Present, and Future

83. Health Disparities in Nephrology

84. Care of the Older Adult with Chronic Kidney Disease

85. Stem Cells, Kidney Regeneration, Gene and Cell Therapy in Nephrology

Authors

Yu, Alan S. L. Harry Statland and Solon Summerfield Professor of Medicine, Director, Division of Nephrology and Hypertension and the Kidney Institute, University of Kansas Medical Center, Kansas City, Kansas.

Chertow, Glenn M. Norman S. Coplon/ Satellite Healthcare, Professor of Medicine, Chief, Division of Nephrology, Stanford University School of Medicine, Stanford, Palo Alto, California, USA.

Luyckx, Valerie Affiliate Lecturer, Renal Division, Brigham and Womens Hospital, Harvard Medical School, Boston, MA, Institute of Biomedical Ethics and the History of Medicine

University of Zurich, Zurich, Switzerland.

Marsden, Philip A. Professor of Medicine, Elisabeth Hofmann Chair in Translational Research, Oreopoulos-Baxter Division Director of Nephrology; Vice Chair Research, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.

Skorecki, Karl Annie Chutick Professor and Chair in Medicine (Nephrology), Technion-Israel Institute of Technology, Director of Medical and Research Development, Rambam Health Care Campus, Haifa, Israel.

Taal, Maarten W. Professor of Medicine, Division of Medical Sciences and Graduate Entry Medicine, University of Nottingham; Honorary Consultant Nephrologist, Department of Renal Medicine, Royal Derby Hospital, Derby, United Kingdom.

For more information about this book visit https://www.researchandmarkets.com/r/klnzw8

View source version on businesswire.com:https://www.businesswire.com/news/home/20191206005135/en/

CONTACT: ResearchAndMarkets.com

Read the original here:
Brenner and Rector's The Kidney, 2-Volume Set. Edition No. 11 - ResearchAndMarkets.com - Associated Press

Stem Cells Market to a Revenue Opportunity of US$270.5 bn During the Period from 2025 – News Description

By Adult Stem Cells

In theglobal stem cells marketa sizeable proportion of companies are trying to garner investments from organizations based overseas. This is one of the strategies leveraged by them to grow their market share. Further, they are also forging partnerships with pharmaceutical organizations to up revenues.

In addition, companies in the global stem cells market are pouring money into expansion through multidisciplinary and multi-sector collaboration for large scale production of high quality pluripotent and differentiated cells. The market, at present, is characterized by a diverse product portfolio, which is expected to up competition, and eventually growth in the market.

Some of the key players operating in the global stem cells market areSTEMCELL Technologies Inc., Astellas Pharma Inc., Cellular Engineering Technologies Inc., BioTime Inc., Takara Bio Inc., U.S. Stem Cell, Inc., BrainStorm Cell Therapeutics Inc., Cytori Therapeutics, Inc., Osiris Therapeutics, Inc., and Caladrius Biosciences, Inc.

As per a report by Transparency Market Research, the global market for stem cells is expected to register a healthy CAGR of 13.8% during the period from 2017 to 2025 to become worth US$270.5 bn by 2025.

Request Sample of Stem Cells Market Report

https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=132

Depending upon the type of products, the global stem cell market can be divided into adult stem cells, human embryonic stem cells, induced pluripotent stem cells, etc. Of them, the segment of adult stem cells accounts for a leading share in the market. This is because of their ability to generate trillions of specialized cells which may lower the risks of rejection and repair tissue damage.

Depending upon geography, the key segments of the global stem cells market are North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. At present, North America dominates the market because of the substantial investments in the field, impressive economic growth, rising instances of target chronic diseases, and technological progress. As per the TMR report, the market in North America will likely retain its dominant share in the near future to become worth US$167.33 bn by 2025.

Investments in Research Drives Market

Constant thrust on research to broaden the utility scope of associated products is at the forefront of driving growth in the global stem cells market. Such research projects have generated various possibilities of different clinical applications of these cells, to usher in new treatments for diseases.

Request for a Discount on Stem Cells Market Report

https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=132

Since cellular therapies are considered the next major step in transforming healthcare, companies are expanding their cellular therapy portfolio to include a range of ailments such as Parkinsons disease, type 1 diabetes, spinal cord injury, Alzheimers disease, etc.

The growing prevalence of chronic diseases and increasing investments of pharmaceutical and biopharmaceutical companies in stem cell research are the key driving factors for the stem cells therapeutics market. The growing number of stem cell donors, improved stem cell banking facilities, and increasing research and development are other crucial factors serving to propel the market, explains the lead analyst of the report.

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through adhoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

ContactTransparency Market ResearchState Tower,90 State Street,Suite 700,Albany NY 12207United StatesTel:+1-518-618-1030USA Canada Toll Free:866-552-3453Email:[emailprotected]Website:http://www.transparencymarketresearch.comResearch Blog:https://theglobalhealthnews.com/

Original post:
Stem Cells Market to a Revenue Opportunity of US$270.5 bn During the Period from 2025 - News Description

Stem cell Therapy Market 2019-2027| Business Scope and Investment Analysis By MEDIPOST, PHARMICELL Co., Ltd, Holostem Terapie Avanzate Srl, Mesoblast…

By Adult Stem Cells

Global Stem cell therapy Market report offers meticulous investigation of current scenario of the global market, which considers numerous market dynamics. This market report identifies and analyses the emerging trends along with key drivers, challenges and opportunities in the industry. Stem cell therapy market report comprises of historic data, present market trends, market environment, technological innovation, upcoming technologies and the technical progress in the related industry. The data and information about Stem cell therapy industry are taken from reliable sources such as websites, annual reports of the companies, and journals, and then validated by the market experts. The Stem cell therapy report covers major manufacturers, suppliers, distributors, traders, customers, investors and major types, major applications.

The finest market research report is the one which is pertinent, unique, and creditable that employs proven tools and techniques to turn complex market insights into simpler version. Being the most suitable example of the above attributes, this Stem cell therapy report has been prepared by keeping in mind every market related aspect. Stem cell therapy market is supposed to grow during the forecast period due to growing demand at the end user level. According to this market report, new highs will take place in the market in 2019-2026. A market research carried out in this report assists in improving and enhancing the products so that future products offer more fulfilment to your valuable customers.

Get Sample Copy of this Report athttps://www.theinsightpartners.com/sample/TIPHE100000991/

MARKET INTRODUCTION

Stem cell therapy is a technique which uses stem cells for the treatment of various disorders. Stem cell therapy is capable of curing broad spectrum of disorders ranging from simple to life threatening. These stem cells are obtained from different sources, such as, adipose tissue, bone marrow, embryonic stem cell and cord blood among others. Stem cell therapy is enables to treat more than 70 disorders, including degenerative as well as neuromuscular disorders. The ability of a stem cell to renew itself helps in replacing the damaged areas in the human body.

Key Competitors In Stem Cell Therapy Market areMEDIPOST, PHARMICELL Co., Ltd, Holostem Terapie Avanzate S.r.l., Mesoblast Ltd, U.S. Stem Cell, Inc., BIOTIME, INC., Lonza, Caladrius, Takeda Pharmaceutical Company Limited, KOLON TISSUEGENE INC.

Market Segmentation:

By Type (Adult Stem Cell Therapy, Embryonic Stem Cell Therapy, Induced Pluripotent Stem Cell Therapy, Other Stem Cell Therapy);

By Treatment (Allogeneic, Autologous); Application (Muscoskeletal, Dermatology, Cardiology, Drug Discovery and Development, Other Applications)

By Geography North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. And 13 countries globally along with current trend and opportunities prevailing in the region.

Overview of the report

The study provides an in-depth analysis of the global market and current & future trends to elucidate imminent investment pockets.

Obtain the most up to date information available in all Market.

Information about key drivers, restraints, opportunities, and their impact analysis on the market size has been provided.

Identify growth segments and opportunities in the industry.

Assess your competitors refining portfolio and its evolution.

Click here to buy full report with all description:-https://www.theinsightpartners.com/buy/TIPHE100000991/

About Us:

The Insight Partnersis a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are committed to provide highest quality research and consulting services to our customers. We help our clients understand the key market trends, identify opportunities, and make informed decisions with our market research offerings at an affordable cost.

We understand syndicated reports may not meet precise research requirements of all our clients. We offer our clients multiple ways to customize research as per their specific needs and budget

Contact Us:

The Insight Partners,

Phone: +1-646-491-9876

Email:[emailprotected]

Read more:
Stem cell Therapy Market 2019-2027| Business Scope and Investment Analysis By MEDIPOST, PHARMICELL Co., Ltd, Holostem Terapie Avanzate Srl, Mesoblast...

Cutting Through the Headlines: Are Scientists Really Growing Sentient "Mini-brains"? – Technology Networks

By Adult Stem Cells

Neuroscience 2019, the worlds biggest conference of brain science, finished just over a month ago. In the wake of some particularly inflammatory headlines, we take a closer look at whether claims that new model systems for studying the brain could produce sentience in a jar have any truth to them.

It must be a matter of some regret to researchers that, when they were first created a few years ago, the temptation to call the three-dimensional balls of neural tissue mini-brains proved too strong to resist.

At the Society for Neurosciences 2019 conference, the catchy, headline magnet term mini-brain had very much been taken out of the lexicon. In a press conference that we attended, the gathered scientific panel had obviously been encouraged to stick to a new term: brain organoid. More abstract than mini-brain, and certainly less likely to feature on a tabloid front cover.

As a session introducing the latest advances in organoid research drew to a close, the rebrand appeared to have worked. There had been no questions about Futurama-style talking heads in jars, or questions of existential cellular dread. So far. But by the end of the session, a dispute rose which highlighted some real doubts among researchers in the field, indicating that the topic of consciousness, let alone consciousness in a jar, was far from settled. But before we get to that, lets take a look at the science behind brain organoids.

The previous days plenary had gone very smoothly. A truly excellent talk by Harvard Stem Cell Institute (HSCI)s Paola Arlotta had shown the care and detail that had gone into organoid science.

Arlotta began her talk by outlining why researchers might consider making three-dimensional neuro-balls (my submission for what brain organoids should really be called) in the first place. Studying the brain is really hard. Its complexity is unrivaled by any other organ in the body and humans tend to object if you try and remove their brain to get a closer look.

As such, biomedical researchers have mainly focused on one of two approaches when attempting to model the incredible intricacy of the brain:

Clearly, neither route is perfect, and teams like Arlottas have been seeking a new model that could potentially take the best of both worlds and put them in one system. Brain organoids were meant to be that model. A lot of work has gone into enabling the creation of such a system, including huge steps in our tools for studying brain development. This requires handling data from more than just one cell type, as Arlotta explained in her lecture:

There are no individual subtypes that develop in isolation. They all develop together and it's really an orchestrated dance of many different cell types being generated. This is the complexity that we have always wanted to provide all at once. All cells, all genes, all stages, except we have never had the technology and methodology that would allow us to do that.

Forget a "brain in a jar". This image shows what pea-size brain organoids at 10 months old actually look like, grown in the Muotri lab at UCSD. Credit: Muotri Lab/UCTV

This changed a few years ago, when we invented amazing single-cell level genomics approaches that now allow us to sequence thousands, to hundreds of thousands, to millions of cells from any tissue any stage of any organism. Arlotta continues. This innovation, alongside computational methods, has permitted researchers to take a widescreen view of brain development.

For Arlottas team, capturing this global picture meant a lot of meticulous work: Basically, we set off to purify and refine, at a single cell level, every single cell of the developing somatosensory cortex, which we sampled every day in the mouse until about P1 [postnatal day 1] when the majority of the cells had been generated. The result: beautiful, detailed plots of the gene expression underlining the development of this region of the mouse brain.

With this information, a blueprint for how a brain organoid should develop, Arlottas team could then go on to create organoids.

The simplicity of this process is something that made even Arlotta do a double take at first. I was skeptical for many years, but then Yoshiki Sasai published what I think is a seminal experiment. Basically, what was shown is that if you take a 3D cluster of embryonic stem cells and you culture them in a dish, without adding much from the outside, these cells have the ability to self-organize and undergo self-morphogenesis to give rise to an optic-cup like structure. This cup has retinal and other cells of the mature eye, responds to light, and even forms morphological layers like an eye does. Sasais work, alongside that of Madeline Lancaster, formed the blueprint for future organoid work. It was published just seven years ago. This is a field advancing at a breakneck speed.

As such, its a field of great interest to the press and general public. To answer questions on her research, Arlotta joined UCSFs Arnold Kriegstein and Michael Nestor from the Hussman Institute for Autism for the next days panel discussion.

The main points from the panel were as follows:

The latter point, addressed by Kriegstein, seems pivotal to the future of this field. He presented results from single-cell RNA-seq (a technique that analyzes genetic material in base-by-base detail) scans of organoids and human brain tissue. The cell types are broadly similar to the ones you find in normally developing tissue, but the problem is that our genetic analysis is showing that they lack specificity, as though their identify is a bit confused, explained Kriegstein.

Images of brain tissue contrasted with organoids clearly show the reduced complexity of the model brains, with fewer cell types and a different developmental timeline. Kriegstein showed that the organoid cells are under a type of cellular stress that seems to limit their ability to mimic normal cells (although when the cells were transplanted into a mouse brain, creating a human-mouse chimera, the stress seemed to reduce). This is both an issue for the organoids potential as a model for brain disease, and for any claims that they might in any way become sentient in any human way.

Arlottas data had suggested that organoids were able to be kept in bioreactors, alive for up to four years. Could the simplified organoids simply not be old enough yet? This is not an adult brain that you make. Its not even a complete younger brain, its very primitive and reductive. There is a limit to what you can do in culture; they only grow to a certain size and they only make certain cells, said Arlotta.

This is a cross-section of a brain organoid, showing the initial formation of a cortical plate. Each color marks a different type of brain cell. Credit:Muotri Lab/UCTV

This point didnt come from a member of the press, but from another researcher. This was Elan Ohayon, co-founder of the San Diego-based Green Neuroscience Laboratory (GNL), who had been quoted in The Guardian in the days before SfN, singing from a very different hymnsheet from the panel. In that article, Ohayon had said, "If there's even a possibility of the organoid being sentient, we could be crossing that line. We don't want people doing research where there is potential for something to suffer." The GNL is also opposed to any captive animal experimentation. In the press event Ohayon professed at length, to a stony-faced response from the panel, why he believed they were underestimating the risk of an ethically dubious outcome from their research.

Ohayon finished by asking whether the researchers felt that the field should be put on hold until more was known about consciousness in the organoids. Nestor, in response, highlighted the lack of cytoarchitecture present to support the conditions needed for sentience, but he was cut off by a sharp retort from Ohayon. Thats incorrect. Actually thats my specialty, he began, before a stressed SfN staffer attempted to get him to sit down. Moving away from the microphone, Ohayon concluded, Its great that you are moving towards human-based research, the real concern is also this move towards chimera without thinking about sentience. You are underestimating where you are going, and its going to get there fast.

To say the least, Ohayons views seem quite at odds with that of the panel (the Green Neuroscience Laboratory did not immediately respond to request for comment for this interview). But, as with much in science, there is perhaps a truth to be found in between these two divergent positions.

Talking later to UC San Diego Professor Alysson Muotri, who has used brain organoids in his lab for years, we began to find evidence of where that midpoint might stand. He explains that he led a panel discussion on ethics in brain organoids, which you can watch below. The panel consisted of experts in both neuroscience and philosophy. Disagreements began with the basic definition of what consciousness is. Christof Koch, Chief Scientist and President of the Allen Brain Institute suggests that the cortex alone could be sufficient for consciousness, whilst Patricia Churchland, and Emerita Professor at UC San Diego suggested that other regions, like a brain stem or thalamus would be required. Other panel members, Muotri told me, argued that: You need a body, a brain connected to a body, otherwise there will be no consciousness coming from the tissue. How can we have a debate about creating a conscious being in a jar, if we dont really know what consciousness is in the first place?

What Muotri does suggest, in place of a halt to research, is a better effort to conduct studies in a more ethical way, similar to how scientists aim to conduct animal research. We don't treat animals badly just because they're for research. We try to give them a good lifestyle. So for the organoids it might be exactly the same thing. We just have to agree on how we should do it. I mean, what are the conditions that we need to keep them alive? How do we discard them? How many of them we should use to answer specific scientific questions? So these are the kinds of debate that we can start right now. But I just think it would be unfair to stop science.

So the potential of organoids, or brains-in-a-dish, or mini-brains, or whatever you want to call them, may be undeniable, but so is the potential of science to go faster than it intends. What scary headlines dont reflect is that scientists are well aware of both these things.

See original here:
Cutting Through the Headlines: Are Scientists Really Growing Sentient "Mini-brains"? - Technology Networks

Global Stem Cells Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2025 – Breaking News Updates

By Adult Stem Cells

The Global Stem Cells Market report study includes an elaborative summary of the Stem Cells market that provides in-depth knowledge of various different segmentations. Stem Cells Market Research Report presents a detailed analysis based on the thorough research of the overall market, particularly on questions that border on the market size, growth scenario, potential opportunities, operation landscape, trend analysis, and competitive analysis of Stem Cells Market. The information includes the company profile, annual turnover, the types of products and services they provide, income generation, which provide direction to businesses to take important steps. Stem Cells delivers pin point analysis of varying competition dynamics and keeps ahead of Stem Cells competitors such as CCBC, Vcanbio, Boyalife, Beikebiotech.

View Sample Report @http://www.marketresearchstore.com/report/global-stem-cells-market-2019-by-manufacturers-regions-491303#RequestSample

The main objective of the Stem Cells report is to guide the user to understand the Stem Cells market in terms of its definition, classification, Stem Cells market potential, latest trends, and the challenges that the Stem Cells market is facing. In-depth researches and Stem Cells studies were done while preparing the Stem Cells report. The Stem Cells readers will find this report very beneficial in understanding the Stem Cells market in detailed. The aspects and information are represented in the Stem Cells report using figures, bar-graphs, pie diagrams, and other visual representations. This intensifies the Stem Cells pictorial representation and also helps in getting the Stem Cells industry facts much better.

.This research report consists of the worlds crucial region market share, size (volume), trends including the product profit, price, Value, production, capacity, capability utilization, supply, and demand and industry growth rate.

Geographically this report covers all the major manufacturers from India, China, the USA, the UK, and Japan. The present, past and forecast overview of the Stem Cells market is represented in this report.

The Study is segmented by following Product Type, Umbilical Cord Blood Stem Cell, Embryonic Stem Cell, Adult Stem Cell, Other

Major applications/end-users industry are as follows Diseases Therapy, Healthcare

Stem Cells Market Report Highlights:

1)The report provides a detailed analysis of current and future market trends to identify the investment opportunities2) In-depth company profiles of key players and upcoming prominent players3) Global Stem Cells Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)4) Strategic recommendations in key business segments based on the market estimations5) To get the research methodologies those are being collected by Stem Cells driving individual organizations.

Research Parameter/ Research Methodology

Primary Research:

The primary sources involve the industry experts from the Global Stem Cells industry including the management organizations, processing organizations, analytics service providers of the industrys value chain. All primary sources were interviewed to gather and authenticate qualitative & quantitative information and determine future prospects.

In the extensive primary research process undertaken for this study, the primary sources industry experts such as CEOs, vice presidents, marketing director, technology & innovation directors, founders and related key executives from various key companies and organizations in the Global Stem Cells in the industry have been interviewed to obtain and verify both qualitative and quantitative aspects of this research study.

Secondary Research:

In Secondary research crucial information about the industry value chain, the total pool of key players, and application areas. It also assisted in market segmentation according to industry trends to the bottom-most level, geographical markets and key developments from both market and technology oriented perspectives.

Inquiry for Buying Report: http://www.marketresearchstore.com/report/global-stem-cells-market-2019-by-manufacturers-regions-491303#InquiryForBuying

Thanks for reading this article, you can also get individual chapter wise section or region wise report versions like North America, Europe or Asia. Also, If you have any special requirements, please let us know and we will offer you the report as you want.

Sorry! The Author has not filled his profile.

Continued here:
Global Stem Cells Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2025 - Breaking News Updates

Whats Happening: IDF Shabbat of Heroes, Sephardic Papers – Jewish Journal

By Adult Stem Cells

FRI DEC 6

Zamru Friday NightShomrei Torah Synagogue holds Zamru Friday Night, a unique, musically rich kabbalat Shabbat service and dinner. Cantor Jackie Rafii and guitarist Daniel Raijman headline the event, Music to Move Your Soul. Guests bring their own kosher wine. 6-9 p.m. Dinner for members: $20 adults, $12 children 12 and under. General: $30 adults, $15 children. Shomrei Torah Synagogue, 7353 Valley Circle Blvd., West Hills. (818) 854-7650.

Middle East DiscussionGiven decades of conflict between the same rivals, punctuated by intermittent treaties, the Middle East is arguably the politically messiest region on earth. Jordan Reimer, policy analyst at the RAND Corp., helps to unpack the conflicts. A scholar who served under two White House administrations and the New York City Police Department, Reimer explains effects of the constant conflicts in the Middle East on Israel and the United States. 6:15 p.m. service. 7:30-9 p.m. lecture. Temple Isaiah, 10345 W. Pico Blvd. (310) 277-2772.

IKAR FeastIt is the first Friday of the month again, which means its time for IKARs monthly TRIBE Feast, a schmooze and groove at food-filled tables with Jewish and Jew-adjacent 20- and 30-somethings. RSVP requested so sufficient food is prepared. 6:30 p.m. Shabbat service. 7:45 p.m. TRIBE Feast. IKARs Event Space, 1729 S. La Cienega Blvd. (323) 634-1870.

Shabbat for WomenLev Eisha, a community of and for joyous Jewish women, celebrates a Shabbat infused with music and enlightened by teachings by Rabbi Toba August. She and cantorial soloist Cindy Paley lead Shabbat services. Everybody is welcome. 8:15 a.m. teaching. 9:30 a.m. service. Beth Shir Shalom, 1827 California Ave., Santa Monica. (310) 575-0985.

Max & Willys Last LaughWhen German comedian Max Ehrlich and his best friend, composer Willy Rosen, were caught in Holland in 1942 and sent to a concentration camp, the commandant recognized Ehrlich. He made an irresistible offer: Every Monday night before the train leaves for Auschwitz, Max and Willy will perform a cabaret. If they are funny, they will perform it the following week. If not, they will be put on the train. The performers carried on for 18 months before finally being sent to Auschwitz. Tonight and Sunday afternoon, Temple Emanuel of Beverly Hills presents a staged reading with live music of Max and Willys Last Laugh. Proceeds benefit Temple Emanuel of Beverly Hills. 8 p.m. tonight, 5 p.m. Sunday. $100 reserved seats, $36 general admission, $18 students. James Bridges Theater at UCLA, 235 Charles E. Young Drive East. (310) 825-6792.

Beth Am Film NightAfter Shabbat ends, Temple Beth Am resumes its film series with Laces, the story of a special needs sons complex relationship with the aging father who abandoned him when he was a child. Film buff Michael Berlin leads a post-film discussion. Snacks served. 7 p.m. $12. Temple Beth Am, 1039 S. La Cienega Blvd. (310) 652-7353.

Shulem Lemmer

Our IDF HeroesAfter a Shabbat of Heroes at Pico-Robertson synagogues Adas Torah, Beth Jacob, Bnai David-Judea and Young Israel of Century City, a meet and greet with heroes of the Israel Defense Forces (IDF) takes place at The Mark. Ezer Mizion, the worlds largest Jewish bone marrow registry, organizes this gathering, highlighting how as of August, 2,000 IDF soldiers have donated their stem cells to 2,000 patients around the world. The evening features musician Shulem Lemmer performing during Havdalah and former Israeli Chief Rabbi Yisrael Meir Lau bringing greetings from the Jewish state. Israeli wines and food served. Adults only. RSVP required. 7:30 p.m. The Mark, W. 9320 Pico Blvd. (310) 247-2266.

Sarah Abrevaya Stein

Family Papers: A Sephardic JourneyFor centuries from the Greek port city of Salonica, the large Levy family of editors and publishers reported how the ever-changing state of modernity affected Sephardic Jews across the Ottoman Empire, including how 20th-century wars altered the borders around them. Historian Sarah Abrevaya Stein shares the true story of a frayed family that has been preserved through their letters. She discusses her award-winning book, Family Papers: A Sephardic Journey Through the Twentieth Century, with race and gender scholar Brenda E. Stevenson. 2 p.m. Free. Skirball Cultural Center, 2701 N. Sepulveda Blvd. (310) 440-4500.

Community Service DayAttention all people who seek to make a difference immediately: The Jewish Federation of Greater Los Angeles Community Service Day lasts all day and is a partnership between Federation and social service organizations working to make life better for their neighbors. Free. Prior registration required. For more information, email volunteer@jewishla.org.

The Golden Gelt RoomJoin the Congregation Kol Ami community in The Golden Gelt Room, for an afternoon of comedy, casino games and pre-Hanukkah celebration. Comedian Liz Glazer performs. Mingle, nosh, drink, play and laugh with Kol Amis inclusive community. 4-6:30 p.m. $100. Congregation Kol Ami, 1200 N. La Brea Ave., West Hollywood. (323) 606-0996..

Hanukkah Angels Gift-Wrapping EventThere still is time to become a Hanukkah Angel in Kehillat Maaravs community mitzvah program. Purchase a gift of any amount for one of 10 Chai Lifeline children with life-threatening illnesses, then bring it to the synagogue starting at 9 a.m. and join the synagogues religious school students in gift-wrapping from 11:30 a.m.-12:30 p.m. Latkes and sufganiyot served. To learn about each childs wish list or to become a Hanukkah Angel, contact Rose or Sharone Weizman at eddirector@km-synagogue.org. 1715 21st St., Santa Monica. (310) 829-0566.

Jewish ID Hanukkah PartyEven though Hanukkah doesnt start for two weeks, Jewish Big Brothers Big Sisters of Los Angeles (JBBBSLA) starts early. Bring the children to Stephen Wise Temple for a huge Hanukkah celebration co-organized by JBBBSLA and Kibbutz Bob Waldorf. Ideal for all ages. Candlemaking, Israeli dancing, dreidel games and camp activities highlight the event. If the $5 per person charge is too expensive (children 3-and-under are admitted free), contact Sofia Varona at (323) 456-1162 or sofia@campbobwaldorf.org. 4 p.m. $5. Stephen Wise Temple, 15500 Stephen S. Wise Drive.

BYTHAX Gospel Choir

Hanukkah and Christmas ConcertWilshire Boulevard Temple stages a performance of peace, love and harmony. The congregations Let There Be Light concert of Hanukkah and Christmas melodies, co-organized by the Faithful Central Bible Church, features performers Dr. Dee, the BYTHAX Gospel Choir, Cantor Don Gurney and the Wilshire Boulevard Temple Adult Choir. Sufganiyot and holiday cookies are served after the concert. 4 p.m. Free. RSVP required. Wilshire Boulevard Temple, 3663 Wilshire Blvd. (213) 388-2401.

Lets Talk About ReligionIn the latest round of American Jewish Universitys (AJU) discussion series Lets Talk About Religion: Jews, Christians and Muslims in Conversation, a Jew and a Muslim examine rival and converging views on Is Life Sacred? Tonights topics are medical ethics, abortion and end-of-life issues, with Rabbi Elliot Dorff, rector and professor in philosophy at AJU, in discussion with Dr. Sana Khan, chairman and founder of theAiM Radiology Medical Group. 7:30-9 p.m. $10. American Jewish University, Alan Shapiro Memorial Synagogue, 15600 Mulholland Drive. (310) 440-1572.

The Holocaust and the Danish ExceptionThe Los Angeles Museum of the Holocaust holds a book signing and artists reception with acclaimed photographer Judy Glickman Lauder. Her photos are on exhibit in Beyond the Shadows: The Holocaust and the Danish Exception. Lauder, a Bay Area native, has been photographing Holocaust sites since the 1980s. She talks about her experiences. 7-8:30 p.m. $10 suggested donation. Los Angeles Museum of the Holocaust in Pan Pacific Park, 100 The Grove Drive. (323) 651-3704.

Have an event coming up? Send your information two weeks prior to the event to ryant@jewishjournal.com for consideration. For groups staging an event that requires an RSVP, please submit details about the event the week before the RSVP deadline.

Excerpt from:
Whats Happening: IDF Shabbat of Heroes, Sephardic Papers - Jewish Journal

Marine Coatings Market is Anticipated to Register a Value of XX Million by the end of 2017 – 2025 – Markets Gazette 24

By Adult Stem Cells

Detailed Study on the Marine Coatings Market

The latest report published by Transparency Market Research on the global Marine Coatings market reveals that the market is expected to grow at a CAGR of ~XX% during the forecast period (2019-2029) and reach a value of ~US$ XX by the end of 2019. Further, by leveraging the data in the report, investors, established players, emerging market players, and stakeholders can develop effective business strategies to cement their position in the global Marine Coatings market.

The report ponders over the micro and macro-economic factors that are expected to shape the growth of the Marine Coatings market in the upcoming decade. The report includes a SWOT analysis of some prominent players in the Marine Coatings market wherein the business prospects of each player are discussed in detail.

Concessions for new customers! Offer expires soon!

Request For Discount On This Report @ https://www.transparencymarketresearch.co/sample/sample.php?flag=D&rep_id=902

Vital Market Information Included in the Report:

The report resolves the following doubts related to the Marine Coatings market:

Request Sample Report @ https://www.transparencymarketresearch.co/sample/sample.php?flag=B&rep_id=902

Marine Coatings Market Bifurcation

The Marine Coatings market is bifurcated into different sections to provide a clear understanding of the various aspects of the market. The growth potential, market share, size, and prospects of each segment and sub-segment is depicted in the report.

segmentation study, geographical analysis, vendor landscape study, and other aspects that could prove to be significant for ensuring a strong growth in the global stem cells market.

Global Stem Cells Market: Trends and Opportunities

The world stem cells market is predicted to attain favorable growth prospects on the back of the positive impact caused by swelling investments from biopharmaceutical and pharmaceutical companies for conducting stem cell research. Increasing incidence of chronic diseases could be another powerful factor augmenting the demand in the market. For the coming years, market growth is anticipated to be cemented with the rise of increasing research and development, high-quality stem cell banking facilities, and rising count of stem cell donors.

Amongst all major types, adult stem cells are projected to secure a high demand in the near future as they could multiply into scores of specialized cells capable of repairing tissue damage and lowering the risks of rejection. Budding segments such as induced pluripotent stem cells could also offer rewarding prospects in the market with the help of their unique traits and advantages.

Global Stem Cells Market: Geographical Analysis

The international stem cells market is foreseen to testify the dominance of North America which has always been at the forefront of the adoption of latest technologies. Besides its impressive technological progress, the region could improve its growth while riding on the increasing prevalence of target chronic disorders, high economic growth, and massive investments in the industry. As a result, the regional market is forecast to showcase a colossal growth in the coming years.

Treading on the heels of North America, Europe could also provide lucrative growth opportunities in the international stem cells market due to factors such as medical tourism. An increasing number of U.S. and Canada patients have been witnessed to travel to Europe for taking treatments made available at economical costs. Asia Pacific is envisioned to exhibit a relatively slower growth in the market due to various reasons.

Global Stem Cells Market: Companies Mentioned

With a view to expand their presence as well as their portfolios when operating in the worldwide stem cells market, players are foretold to work out strategic partnerships and collaborations with pharmaceutical firms. Moreover, they could look to raise funds with the help of overseas organizations to introduce new stem cell-based therapies in the market. Some of the leading companies in the market could be Cellular Engineering Technologies Inc., Astellas Pharma Inc., and STEMCELL Technologies Inc.

Global Stem Cells Market by Product

Global Stem Cells Market by Source

Global Stem Cells Market by Application

Global Stem Cells Market by End User

Global Stem Cells Market by Geography

RequestTOC For ThisReport @ https://www.transparencymarketresearch.co/sample/sample.php?flag=T&rep_id=902

What Sets TMR Apart From the Rest?

See the rest here:
Marine Coatings Market is Anticipated to Register a Value of XX Million by the end of 2017 - 2025 - Markets Gazette 24

→←